Drug intelligence / Profile preview

iSCLife

Development stage: Unknown
Lead developer: SCL Science
Modality: Stem Cell Therapies → Cell Therapies
Administration: Injection

Overview

iSCLife is an allogeneic cell therapy product composed of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs), developed by SCL Science. The therapy leverages the innate regenerative and immunomodulatory capabilities of MSCs to treat chronic pain conditions. By secreting bioactive molecules and interacting with the host immune system, iSCLife aims to reduce inflammation and facilitate tissue repair at the site of injury or degeneration. It is currently being evaluated in Phase 1/2 clinical trials for various pain-related indications, where it is intended to modulate the inflammatory environment and promote healing in damaged tissues.

Brand names: iSCLife
Other names: human umbilical cord mesenchymal stem cellsiSCL stem cells

Beyond the preview

Go deeper on iSCLife.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iSCLife.

Explore the full profile